In a second round of Series C funding, Apollo Therapeutics has raised $33.5m to advance its pipeline programmes. This brings the total funds raised by the company in 2023 to $260m. Healthcare investment company Patient Square Capital led the funding round, with participation from new investors including M&G, as well as two US public pension plans. Existing investor Rock Springs Capital also contributed. Apollo plans to use the funds to advance the development of its pipeline programmes and to support its drug discovery and development efforts. The company focuses on transforming basic medical research into therapies using a hub-and-spoke model that merges practices from big pharma and venture capital.
Key points:
- Apollo Therapeutics has raised $33.5m in a second round of Series C funding to advance its pipeline programmes.
- Healthcare investment company Patient Square Capital led the funding round, with participation from new investors including M&G and two US public pension plans.
- The funding will be used to advance Apollo’s pipeline and to support its drug discovery and development efforts.
- Apollo focuses on transforming basic medical research into therapies using a hub-and-spoke model.
